5AM Venture Management sold 170,000 shares of Praxis Precision Medicines in the fourth quarter. The quarter-end position value decreased by $9.01 million as a result of the move, which marked a full ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes ...
DALLAS--(BUSINESS WIRE)--SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, today announced that data from its platform ...
With a state-of-the-art lab and an advisory committee featuring local employers, the biotechnology program launching this fall at Omaha's Metropolitan Community College aims to equip students to enter ...
Superstring Capital Management reduced its stake in Terns by 345,869 shares during the fourth quarter; the estimated trade value was $7.99 million based on quarterly average prices. Meanwhile, the ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is a ...
The MarketWatch News Department was not involved in the creation of this content. In a year defined by global disruption and rapidly evolving geopolitical risk, GardaWorld invites ISC West attendees ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
New platform empowers security integrators and guard companies to scale fast-growing mobile surveillance businesses with complete operational visibility and control Launch and Scale Your Mobile ...
When Gossamer Bio announced poor results from its flagship blood pressure study in February, the San Diego company’s stock dropped by 78% in value. Now, it’s slashing its staff. The biotech lab began ...
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results